Home » Novo Buys Rights to Early Obesity Pill For $2.6 Billion

Novo Buys Rights to Early Obesity Pill For $2.6 Billion

September 29, 2026September 29, 2026

This post was originally published on this site.

The Wegovy maker has signed a deal to license an experimental obesity pill from China’s Jiangsu Hengrui Pharmaceuticals as it seeks to regain share of the global GLP-1 market.

FlashNews:

Rural E-Commerce May Help Farmers Produce More With Less Land, New Study Finds

US 30-year Treasury yield hits highest since 2002

Sir Ranulph Fiennes’ relatives tell BBC it’s ‘very painful’ not being able to visit him

ECB puts AI agent payments on the digital euro drawing board

The Politics of Duping

Taylor Swift dominated the VMAs, but do music videos still matter?

I Found National Coffee Day Deals Worth Making Coffee at Home For (2026)

A Republican midterm defeat will not be an earthquake

Autumn food stars: what to cook, plant and pick now

Sephora to Launch at Marks & Spencer

Novo Buys Rights to Early Obesity Pill For $2.6 Billion

US-Iran war adds €100bn to EU’s fuel bill

Oura Delays US IPO

Ethereum schedules Glamsterdam upgrade on Sepolia for Oct. 6

How to Beat Surveillance Pricing Before It Bleeds You Dry

7 Best Smartwatch Models: Apple, Google, Garmin (2026)

OpenAI Delays Release of Latest Model Over Safety Concerns

Timnit Gebru Believes There Is No ‘Existential Threat’ From AI

Celine Dion kicks off Paris Fashion Week with surprise performance

US crypto ETF inflows cool after $3.3B week but streaks hold

Novo Buys Rights to Early Obesity Pill For $2.6 Billion